Carboplatin and etoposide for recurrent malignant glioma following surgical and radiotherapy failure: A clinical study conducted at the Northern Israel Oncology Center

Journal of Surgical Oncology

Volumn 71, Issue 3, 1999, Pages 167-170

  Stein, Moshe E ^a,b   Kuten, Abraham ^a   Drumea, Karen ^a   Goldsher, Dorith ^a   Tzuk Shina, Zahala ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Carboplatin; Etoposide; Recurrent brain glioma

Indexed keywords

AMINOTRANSFERASE; CARBOPLATIN; ETOPOSIDE; STEROID;

ADULT; ARTICLE; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; EROSIVE GASTRITIS; FEMALE; GLIOBLASTOMA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ISRAEL; LIVER TOXICITY; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; THROMBOCYTOPENIA; TREATMENT FAILURE; TUMOR RECURRENCE;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARBOPLATIN; ETOPOSIDE; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0032779425     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9098(199907)71:3<167::AID-JSO6>3.0.CO;2-V     Document Type: Article

References (12)

1. Walker MD, Hurwitz BS: BCNU 1, 3-bis (2chloroethyl-)-1-nytrosourea (NSC-409962) in the treatment of malignant brain tumor: A preliminary report. Cancer Chemother Rep 1970;54: 236-271.
2. Newton HB, Bromberg J, Junck L, et al.: Comparison between BCNU and procarbazine chemotherapy for treatment of Gliomas. J Neurooncol 1989;64:2420-2423.
3. Yung WK, Mechtler L, Gleason MJ: Intravenous carboplatin for recurrent malignant gliomas: A phase II study. J Clin Oncol 1991; 9:860-864.
4. Dodion P, Sanders C, Georges P, et al.: In vitro chemosensitivity of brain tumors to cisplatin and its analogues, iproplatin and carboplatin. Cancer Chemother Pharmacol 1988;22:80-82.
5. Jeremic B, Grujicic D, Jevremovic S, et al.: Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: A phase II study. J Clin Oncol 1992;10:1074-1077.
6. Levin VA, Prados MD: Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosurea resistance. J Clin Oncol 1992;10:766-771.
7. Longee DC, Friedman HS, Albright RE, et al.: Treatment of patients with recurrent gliomas with cyclophosphamide and vincristine. J Neurosurg 1990;72:583-588.
8. Brada M, Sharpe G: Editorial: Chemotherapy of high-grade gliomas: Beginning of a New Era or the end of the Old? Eur J Cancer 1996;32A:2193-2194.
9. MacDonald DR, Cascino TL, Schold SC, et al.: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-1280.
10. Rajan B, Ross G, Lim CC, et al.: Survival in patients with recurrent glioma as a measure of treatment efficacy: Prognostic factors following nitrosurea chemotherapy. Eur J Cancer 1994;30A: 1809-1815.
11. Sanson M, Ameri A, Monjour A, et al.: Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: A phase II study. Eur J Cancer 1996;32A:2229-2235.
12. Giannone L, Wolff SN: Phase II treatment of central nervous system gliomas with high-dose etoposide and autologous bone marrow transplantation. Cancer Treat Rep 1987;71:759-761.